Your browser is no longer supported. Please, upgrade your browser.
Settings
JAGX Jaguar Health, Inc. daily Stock Chart
JAGX [NASD]
Jaguar Health, Inc.
Index- P/E- EPS (ttm)-18.36 Insider Own10.37% Shs Outstand32.16M Perf Week-9.18%
Market Cap15.50M Forward P/E- EPS next Y-0.46 Insider Trans0.00% Shs Float16.07M Perf Month5.00%
Income-44.80M PEG- EPS next Q-0.15 Inst Own3.60% Short Float1.78% Perf Quarter0.00%
Sales5.10M P/S3.04 EPS this Y-311.40% Inst Trans-17.37% Short Ratio0.10 Perf Half Y-39.68%
Book/sh0.32 P/B1.48 EPS next Y0.00% ROA-126.90% Target Price- Perf Year-89.25%
Cash/sh0.04 P/C12.92 EPS next 5Y40.00% ROE-775.40% 52W Range0.35 - 4.84 Perf YTD-40.70%
Dividend- P/FCF- EPS past 5Y- ROI-208.00% 52W High-90.19% Beta0.79
Dividend %- Quick Ratio0.30 Sales past 5Y- Gross Margin28.20% 52W Low35.42% ATR0.05
Employees29 Current Ratio0.40 Sales Q/Q-43.80% Oper. Margin- RSI (14)43.95 Volatility7.26% 10.87%
OptionableNo Debt/Eq1.56 EPS Q/Q-131.10% Profit Margin- Rel Volume0.57 Prev Close0.48
ShortableYes LT Debt/Eq0.08 EarningsMay 15 BMO Payout- Avg Volume2.74M Price0.47
Recom2.00 SMA20-7.58% SMA50-4.27% SMA200-27.97% Volume1,566,971 Change-1.19%
Jul-11-17Initiated Rodman & Renshaw Buy $2
Jul-02-20 08:30AM  
Jun-29-20 08:30AM  
Jun-25-20 06:55AM  
Jun-23-20 05:32PM  
08:30AM  
Jun-22-20 08:30AM  
Jun-19-20 05:15PM  
Jun-10-20 11:13PM  
Jun-03-20 10:07AM  
May-28-20 08:30AM  
May-26-20 08:30AM  
May-22-20 09:00AM  
May-20-20 08:30AM  
May-15-20 04:15PM  
08:00AM  
May-13-20 08:30AM  
May-12-20 11:45AM  
08:30AM  
May-03-20 04:11PM  
Apr-16-20 08:30AM  
Apr-06-20 08:00AM  
Apr-03-20 08:30AM  
Apr-02-20 08:30AM  
Apr-01-20 08:30AM  
Mar-12-20 08:30AM  
Mar-09-20 01:46PM  
Mar-05-20 08:30AM  
Feb-20-20 08:45AM  
Feb-06-20 08:30AM  
Jan-08-20 08:30AM  
Jan-07-20 08:50AM  
Dec-16-19 08:30AM  
Dec-10-19 08:30AM  
Nov-21-19 08:30AM  
Nov-20-19 09:15AM  
09:00AM  
Nov-14-19 08:30AM  
08:00AM  
Nov-13-19 08:30AM  
Nov-12-19 08:30AM  
Nov-05-19 07:30AM  
Oct-30-19 08:30AM  
Oct-23-19 08:30AM  
Oct-22-19 08:43AM  
Oct-18-19 10:23AM  
Oct-15-19 08:00AM  
08:00AM  
Oct-11-19 08:14AM  
Oct-10-19 08:30AM  
Oct-04-19 08:30AM  
Oct-01-19 08:30AM  
Sep-30-19 10:16AM  
08:30AM  
Sep-26-19 08:30AM  
Sep-24-19 08:00AM  
Sep-23-19 08:30AM  
Sep-19-19 08:30AM  
Sep-18-19 08:30AM  
Sep-16-19 08:30AM  
Sep-09-19 08:30AM  
Aug-26-19 08:30AM  
Aug-22-19 08:30AM  
Aug-20-19 08:30AM  
Aug-19-19 04:58PM  
12:40PM  
08:30AM  
Aug-16-19 08:30AM  
Aug-15-19 08:55AM  
Aug-14-19 05:15PM  
Aug-07-19 08:30AM  
Aug-02-19 08:30AM  
Jul-26-19 12:00PM  
Jul-23-19 04:05PM  
Jul-18-19 08:30AM  
Jul-15-19 08:00AM  
Jul-11-19 09:00AM  
Jun-28-19 08:00AM  
Jun-26-19 08:00AM  
Jun-25-19 07:15AM  
Jun-24-19 08:00PM  
Jun-19-19 08:00AM  
Jun-18-19 08:00AM  
Jun-11-19 08:00AM  
Jun-06-19 08:00AM  
Jun-05-19 08:00AM  
Jun-03-19 08:00AM  
May-29-19 08:00AM  
May-24-19 04:15PM  
08:30AM  
Apr-25-19 08:00AM  
Apr-10-19 09:22AM  
Apr-02-19 06:00AM  
Apr-01-19 08:05AM  
Mar-28-19 06:00AM  
Mar-27-19 02:35PM  
Mar-20-19 06:30AM  
Mar-18-19 02:00PM  
Mar-05-19 09:00AM  
Feb-25-19 12:00PM  
Feb-21-19 02:09PM  
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. It operates through two reportable segments, Human Health and Animal Health. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its human health product pipelines include crofelemer, which is in Phase III clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, idiopathic/functional diarrhea, and irritable bowel; and SB-300, a second-generation anti-secretory agent for various indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of chemotherapy-induced diarrhea in dogs; and Equilevia, a non-prescription product for total gut health in equine athletes. In addition, its products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Siegel Jonathan B.DirectorJul 23Buy2.0012,70525,41013,276Jul 25 04:09 PM
BOCHNOWSKI JAMES JDirectorJul 23Buy2.00180,582361,164181,618Jul 25 04:08 PM